Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2016 06:15 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Janssen advancing triple combination...
September 01, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
August 11, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference

NEW HAVEN, Conn., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by...
August 09, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference

NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
August 04, 2016 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Second Quarter 2016 Financial Results

NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
June 01, 2016 16:02 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Three Upcoming Investor Conferences

NEW HAVEN, Conn., June 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
May 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs

- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...
April 28, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference

NEW HAVEN, Conn., April 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
March 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
February 25, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports 2015 Fourth Quarter and Year-End Financial Results

NEW HAVEN, Conn., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve month periods ending December 31, 2015. ...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right